贝那普利联合羟苯磺酸钙治疗糖尿病肾病疗效观察

目的 评价贝那普利联合羟苯磺酸钙治疗早期糖尿病肾病的临床疗效.方法 将66例早期糖尿病肾病患者随机分为两组各33例,实验组给予贝那普利与羟苯磺酸钙胶囊联合治疗；对照组给予贝那普利治疗,总疗程3个月.比较治疗前、后两组患者24 h蛋白尿总量、血肌酐(Scr)、尿素氮(BUN)和24h尿蛋白排泄率(24h UAER)等指标的变化及药物不良反应.结果 治疗后,两组患者24h UAER和24h蛋白尿总量水平均较治疗前显著降低(P＜0.05),但实验组患者24h UAER下降较对照组更具显著性(P＜0.05)；两组患者均无血肌酐、尿素氮水平增高,未出现药物不良反应.结论 羟苯磺酸钙与贝那普利联合治疗能有效降低糖尿病肾病患者的尿白蛋白水平,不会因加重肾血流量的减少而加重氮质血症.

Curative effect of benazepril combined with calcium dobesilate for diabetic nephropathy

Objective To investigate the curative effect of benazepril combined with calcium dobesilate in patients with diabetic nephropathy. Methods Sixty-six patients with early diabetic nephropathy were divided into trail group (n=33) and control group (n=33). The patients in the trial group were given benazepril combined with calcium dobesilate, and those in the control group were given benazepril only, with the total treatment time of 3 months. Serum levels of creatinine (Scr), urea nitrogen (BUN), and 24-hour urinary albumin excretion rate (24h UAER) in two groups were observed and compared before and after treatment, the adverse reactions before and after treatment were also observed. Results After treatment for 3 months, the levels of 24 h UAER, 24 h urine protein were decreased significantly in two groups (all the P<0.05). The decrease of 24 h UAER was more significantly in trial group compared with that in control group (all P<0.05). Serum creatinine and urea nitrogen didn’t increase, without any adverse reactions. Conclusion Benazepril combined with calcium dobesilate was effective in the decrease of urine protein for patients with diabetic nephropathy, with no reduction of renal blood flow and aggravation of azotemia.